Skip to main content
OpenTrials
Completed

NCT Number: NCT02519374

Fiber Tolerability in Children

Assessment of the digestive tolerability of the PROMITOR® .

Completed

Looking for future studies?

Notify Me

Key information

Age range

8 year–12 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Biofortis, Saint-Herblain, France

Loading trial locations.

About this study

The trial will be multicenter, double-blind, placebo-controlled, randomized with a 4-arm parallel-design. The subjects wil be randomized to one of the four arms, i.e. four doses of investigational product balanced in maltodextrin, given at the doses of 6, 9 or 12 g (corresponding to 4, 6, or 8 g of fibers) twice a day with the meals of the morning and of the evening versus control (maltodextrin, no fibers) over one week of intake.

The total sample size is 40 healthy children from 8 to 12 years old, male and female.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy children,
  • Aged between 8 and 12 years old included
  • Acceptance of the taste of the product
  • Having breakfast on daily basis
  • Consent and/or assent received according to regulation
  • Informed consent of one of the parents/guardians (for the study to be conducted in Switzerland, in respect with the Swiss regulation) or Informed consent of both parents/guardians (for the study to be conducted in France, in respect with the French regulation)
  • Parents/guardians affiliated to a health insurance (only for the study to be conducted in France, in respect with the French regulation)

Exclusion criteria

  • Specific food regimen
  • Intolerability or food allergy
  • Antibiotic or any medication impacting the gut transit during the 2 weeks before the study
  • Chronic gastrointestinal disease
  • Gastroenteritis in the 2 weeks preceding the study
  • Constipation or diarrhea based on ROMEIII criteria (in average: more than 3 stools per day or less than 3 stools per week)
  • Children and parents expected not to understand and perform the trial correctly (i.e.: troubles in learning and/or speaking)
  • Child in a situation which, in the opinion of the principal investigator, could interfere with the optimal participation to the study or constitute a particular risk of non-compliance
  • Having participated in another clinical trial for 1 month, or currently participating in a clinical trial
  • Under legal protection or deprived from his rights following administrative or judicial decision (only for the study to be conducted in France, in respect with the French regulation)

Treatment and study plan

Placebo (including Maltodextrin)

Drug

PROMITOR® (including Maltodextrin)

Drug

Investigational product dose 1

Primary outcomes

  1. Assessment of the digestive tolerability of the Investigational Product (abdominal pain)

    Time frame: 7 days of intake

    Using analog visual scale

  2. Assessment of the digestive tolerability of the Investigational Product (rumbling)

    Time frame: 7 days of intake

    Using analog visual scale

  3. Assessment of the digestive tolerability of the Investigational Product (bloating)

    Time frame: 7 days of intake

    Using analog visual scale

  4. Assessment of the digestive tolerability of the Investigational Product (flatulence)

    Time frame: 7 days of intake

    Using analog visual scale

  5. Assessment of the digestive tolerability of the Investigational Product (stools consistency & frequency)

    Time frame: 7 days of intake

    Using analog visual scale

Sponsors and collaborators

Lead sponsor

Société des Produits Nestlé (SPN)

Industry

Registry information

Acronym: FITIC

Important dates

Study start
2015
Primary completion
2015
Study completion
2015
First posted
Aug 10, 2015
Registry last updated
Feb 5, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.